2025-08-08T23:08:25.946580+0800 INFO SYS-test function started
2025-08-08T23:08:25.946719+0800 INFO CONFIG-Config path: configs/test_standard.json
2025-08-08T23:08:25.946796+0800 INFO CONFIG-Config: {'chat_config': {'chat_model': 'Qwen/Qwen3-8B', 'lora': False, 'chat_model_type': 'instruction', 'chat_model_inference_engine': 'openai_compatible', 'chat_system_message': 'You are a helpful assistant.', 'chat_parameters': {'temperature': 0.6}, 'chat_max_new_token': 500, 'chat_request_timeout': 60}, 'emb_config': {'emb_model_name': 'Qwen/Qwen3-Embedding-4B', 'emb_size': 2560, 'embedding_timeout': 60}, 'env_config': {'trading_symbols': ['JNJ'], 'warmup_start_time': '2020-03-12', 'warmup_end_time': '2020-03-20', 'test_start_time': '2020-03-23', 'test_end_time': '2020-03-31', 'momentum_window_size': 3, 'env_data_path': {'JNJ': 'data/jnj.json'}}, 'portfolio_config': {'trading_symbols': ['JNJ'], 'type': 'single-asset', 'cash': 100000, 'look_back_window_size': 3}, 'agent_config': {'agent_name': 'test_agent', 'trading_symbols': ['JNJ'], 'character_string': {'JNJ': 'You are an investment expert of Johnson & Johnson (JNJ). You have knowledge about pharmaceuticals, medical devices, and consumer health sectors.'}, 'top_k': 5, 'memory_db_config': {'memory_db_endpoint': 'http://localhost:6333', 'memory_importance_upper_bound': 100.0, 'memory_importance_score_update_step': 18.0, 'trading_symbols': ['JNJ'], 'short': {'db_name': 'short', 'importance_init_val': 50.0, 'decay_recency_factor': 3.0, 'decay_importance_factor': 0.92, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_upper_threshold': 55.0}, 'mid': {'db_name': 'mid', 'importance_init_val': 60.0, 'decay_recency_factor': 90.0, 'decay_importance_factor': 0.96, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_lower_threshold': 55.0, 'jump_upper_threshold': 85.0}, 'long': {'db_name': 'long', 'importance_init_val': 90.0, 'decay_recency_factor': 365.0, 'decay_importance_factor': 0.96, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_lower_threshold': 85.0}, 'reflection': {'db_name': 'reflection', 'importance_init_val': 80.0, 'decay_recency_factor': 365.0, 'decay_importance_factor': 0.98, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'similarity_threshold': 0.95}}}, 'meta_config': {'run_name': '250808_230347_Qwen_Qwen3-8B_JNJ', 'timestamp': '250808_230347', 'model_name': 'Qwen_Qwen3-8B', 'symbols': 'JNJ', 'base_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ', 'momentum_window_size': 3, 'warmup_checkpoint_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint', 'warmup_output_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_output', 'test_checkpoint_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint', 'test_output_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/test_output', 'result_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/final_result', 'log_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/log', 'report_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/report.md', 'csv_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/trading_results.csv', 'charts_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/charts'}}
2025-08-08T23:08:25.946994+0800 INFO ENV-Creating MarketEnvironment with params: env_data_pkl {'JNJ': 'data/jnj.json'}, start_date 2020-03-23, end_date 2020-03-31, symbol ['JNJ']
2025-08-08T23:08:25.949519+0800 INFO ENV-Final date series (intersection): [datetime.date(2020, 3, 23), datetime.date(2020, 3, 24), datetime.date(2020, 3, 25), datetime.date(2020, 3, 26), datetime.date(2020, 3, 27), datetime.date(2020, 3, 30), datetime.date(2020, 3, 31)]
2025-08-08T23:08:25.949569+0800 INFO ENV-Simulation-Length: 7
2025-08-08T23:08:25.949662+0800 INFO SYS-Initializing FinMemAgent
2025-08-08T23:08:25.949786+0800 INFO SYS-Initializing MemoryDB
2025-08-08T23:08:26.051946+0800 INFO SYS-Portfolio type: single-asset
2025-08-08T23:08:26.054419+0800 INFO SYS-Initializing MemoryDB
2025-08-08T23:08:26.129822+0800 INFO **************************************************
2025-08-08T23:08:26.129927+0800 INFO ENV- current date: 2020-03-23, future date: 2020-03-24
2025-08-08T23:08:26.130030+0800 INFO ENV-Current price: {'JNJ': 98.88835144042969}, future price diff: {'JNJ': -0.07234127485612384}
2025-08-08T23:08:26.130071+0800 INFO ENV-Current news: {'JNJ': ['The global medical aesthetic market is projected to grow at a CAGR of 11% from 2019 to 2024, driven by the increasing adoption of minimally invasive procedures, technological advancements, and rising demand among men. Key players in the market include Johnson & Johnson (JNJ), which is positioned to benefit from these trends. The market is segmented by product types such as facial aesthetic products, body contouring devices, and cosmetic implants, and by end-users including clinics, medical spas, and beauty centers. North America, Europe, and Asia Pacific are expected to see significant growth, with North America leading due to high consumer awareness and advanced healthcare infrastructure. Strategic initiatives like mergers, acquisitions, and new product developments are critical for maintaining competitive advantage in this rapidly evolving market. (Sentiment: positive)', "The haircare market in Africa is projected to grow by USD 936.32 million from 2020 to 2024, with a compound annual growth rate (CAGR) of 7%. Key growth drivers include increasing demand for natural haircare products and strategic partnerships between vendors and salons. The market is segmented by product types such as shampoo, conditioner, hair color, hair styling products, and other haircare products, and by distribution channels including offline and online. Geographic segmentation covers Kenya, Nigeria, South Africa, and the rest of Africa. Prominent vendors in this market include major companies like Johnson & Johnson, L'Oréal SA, and Unilever Group, indicating a competitive landscape with significant opportunities for investment. (Sentiment: positive)"]}
2025-08-08T23:08:26.130114+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:08:26.130141+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:08:26.130164+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:08:26.130188+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:08:26.130223+0800 INFO ENV-new info from env
2025-08-08T23:08:26.130250+0800 INFO ENV-date: 2020-03-23
2025-08-08T23:08:26.130275+0800 INFO ENV-price: {'JNJ': 98.88835144042969}
2025-08-08T23:08:26.130305+0800 INFO ENV-news-JNJ-0: The global medical aesthetic market is projected to grow at a CAGR of 11% from 2019 to 2024, driven by the increasing adoption of minimally invasive procedures, technological advancements, and rising demand among men. Key players in the market include Johnson & Johnson (JNJ), which is positioned to benefit from these trends. The market is segmented by product types such as facial aesthetic products, body contouring devices, and cosmetic implants, and by end-users including clinics, medical spas, and beauty centers. North America, Europe, and Asia Pacific are expected to see significant growth, with North America leading due to high consumer awareness and advanced healthcare infrastructure. Strategic initiatives like mergers, acquisitions, and new product developments are critical for maintaining competitive advantage in this rapidly evolving market. (Sentiment: positive)
2025-08-08T23:08:26.130331+0800 INFO --------------------------------------------------
2025-08-08T23:08:26.130355+0800 INFO ENV-news-JNJ-1: The haircare market in Africa is projected to grow by USD 936.32 million from 2020 to 2024, with a compound annual growth rate (CAGR) of 7%. Key growth drivers include increasing demand for natural haircare products and strategic partnerships between vendors and salons. The market is segmented by product types such as shampoo, conditioner, hair color, hair styling products, and other haircare products, and by distribution channels including offline and online. Geographic segmentation covers Kenya, Nigeria, South Africa, and the rest of Africa. Prominent vendors in this market include major companies like Johnson & Johnson, L'Oréal SA, and Unilever Group, indicating a competitive landscape with significant opportunities for investment. (Sentiment: positive)
2025-08-08T23:08:26.130384+0800 INFO --------------------------------------------------
2025-08-08T23:08:26.130407+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:08:26.130430+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:08:26.130453+0800 INFO ==================================================
2025-08-08T23:08:26.130494+0800 INFO AGENT-Step, date: 2020-03-23, run mode: RunMode.TEST, task type: TaskType.SingleAsset
2025-08-08T23:08:26.130518+0800 INFO AGENT-Handling new information
2025-08-08T23:08:26.595118+0800 INFO AGENT-Querying memories
2025-08-08T23:08:27.156406+0800 INFO ##################################################
2025-08-08T23:08:27.156481+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:08:27.156513+0800 INFO AGENT-Short Memory: 22, The global medical aesthetic market is projected to grow at a CAGR of 11% from 2019 to 2024, driven by the increasing adoption of minimally invasive procedures, technological advancements, and rising demand among men. Key players in the market include Johnson & Johnson (JNJ), which is positioned to benefit from these trends. The market is segmented by product types such as facial aesthetic products, body contouring devices, and cosmetic implants, and by end-users including clinics, medical spas, and beauty centers. North America, Europe, and Asia Pacific are expected to see significant growth, with North America leading due to high consumer awareness and advanced healthcare infrastructure. Strategic initiatives like mergers, acquisitions, and new product developments are critical for maintaining competitive advantage in this rapidly evolving market. (Sentiment: positive)
2025-08-08T23:08:27.156543+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156592+0800 INFO AGENT-Short Memory: 23, The haircare market in Africa is projected to grow by USD 936.32 million from 2020 to 2024, with a compound annual growth rate (CAGR) of 7%. Key growth drivers include increasing demand for natural haircare products and strategic partnerships between vendors and salons. The market is segmented by product types such as shampoo, conditioner, hair color, hair styling products, and other haircare products, and by distribution channels including offline and online. Geographic segmentation covers Kenya, Nigeria, South Africa, and the rest of Africa. Prominent vendors in this market include major companies like Johnson & Johnson, L'Oréal SA, and Unilever Group, indicating a competitive landscape with significant opportunities for investment. (Sentiment: positive)
2025-08-08T23:08:27.156624+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156645+0800 INFO AGENT-Short Memory: 19, ChroniSense Medical has appointed Bridget Ross as CEO, effective February 10, 2020. Ross brings over three decades of leadership experience, including roles at Henry Schein and Johnson & Johnson (J&J), where she led significant growth and operational efficiencies. Her appointment is expected to drive ChroniSense to a leading position in the disease management space with its Polso wearable device. This move highlights Ross's successful track record at J&J, particularly in commercial operations and product development. Investors in J&J might view this as a positive reflection of the company's ability to cultivate high-caliber leaders who are sought after by other innovative firms. (Sentiment: positive)
2025-08-08T23:08:27.156677+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156697+0800 INFO AGENT-Short Memory: 20, The global Lateral Flow Assay market is projected to grow by $3.8 billion, driven by a compounded annual growth rate (CAGR) of 7.4%, with the Kits & Reagents segment expected to grow at over 7.7% and reach $5.7 billion by 2025. The United States will maintain a 6.2% growth momentum, while China is expected to grow at 11%, adding approximately $1 billion in market opportunity. Key players in the market include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, and Johnson & Johnson (JNJ). The market growth is driven by factors such as the expanding aging population, increase in chronic diseases, and rising popularity of point-of-care testing. Innovations and product launches in the Lateral Flow Assay space are expected to further drive market growth, making it a promising area for investment. (Sentiment: positive)
2025-08-08T23:08:27.156721+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156741+0800 INFO AGENT-Short Memory: 17, Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a New Drug Application (NDA) to the U.S. FDA for ponesimod, an investigational treatment for adults with relapsing multiple sclerosis (MS). The NDA is supported by the Phase 3 OPTIMUM study, which demonstrated ponesimod's superior efficacy in reducing annualized relapse rate (ARR) and fatigue symptoms compared to Aubagio. The study also showed a significant reduction in combined unique active lesions (CUALs) in the brain. The safety profile of ponesimod was consistent with previous studies and other S1P receptor modulators. Investors should note the potential market impact given the high prevalence of MS and the unmet needs in its treatment. (Sentiment: positive)
2025-08-08T23:08:27.156761+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156782+0800 INFO AGENT-Reflection Memory: 21, The positive price fluctuation (0.0563557191517564) is likely driven by short-term positive sentiment (IDs 16, 17, 18) highlighting JNJ's pharmaceutical advancements, such as the ponesimod NDA submission (ID 17), strong RA drug portfolio (ID 15), and leadership appointments (ID 16). These developments reinforce investor confidence in JNJ's innovation and market positioning, particularly in disease management and healthcare technologies. The reflection-term information (ID 18) explicitly attributes this upward movement to such positive news, suggesting optimism about the company's future prospects despite broader market uncertainties mentioned in other IDs.
2025-08-08T23:08:27.156803+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156822+0800 INFO AGENT-Reflection Memory: 18, The positive price fluctuation of 0.0586 is likely influenced by the positive sentiment from short-term news (IDs 17, 16, 12) highlighting JNJ's advancements in pharmaceuticals (e.g., ponesimod NDA submission, RA drug portfolio strength, and surgical robotics growth). These developments may have boosted investor confidence in JNJ's innovation and market positioning, despite the reflection-term information (IDs 6, 14, 11, 1) noting that broader market factors or unmentioned events could also play a role.
2025-08-08T23:08:27.156842+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156861+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:08:27.156884+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156903+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:08:27.156928+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156948+0800 INFO AGENT-Reflection Memory: 1, The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:08:27.156968+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:08:27.156989+0800 INFO AGENT-Single asset task
2025-08-08T23:09:03.481344+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:09:03.879810+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:09:03.879864+0800 INFO AGENT-summary reason: The investment decision is based on strong positive short-term sentiment from multiple sources (IDs 16, 17, 18, 20, 22, 23) highlighting JNJ's pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), leadership appointments, and market growth opportunities in medical aesthetics and lateral flow assays. These factors reinforce investor confidence in JNJ's innovation and competitive positioning, despite some unexplained price fluctuations (IDs 6, 11) attributed to broader market or external factors.
2025-08-08T23:09:03.880099+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 18, 'feedback': -1}]}
2025-08-08T23:09:03.929959+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/agent/memory_db/brain
2025-08-08T23:09:03.956252+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:09:03.956403+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:09:03.956510+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:09:03.956558+0800 INFO **************************************************
2025-08-08T23:09:03.956595+0800 INFO ENV- current date: 2020-03-24, future date: 2020-03-25
2025-08-08T23:09:03.956756+0800 INFO ENV-Current price: {'JNJ': 106.04206085205078}, future price diff: {'JNJ': -0.0018460847771571561}
2025-08-08T23:09:03.956813+0800 INFO ENV-Current news: {'JNJ': ["The Global Tumor Ablation Market is projected to grow at a CAGR of 10.9%, reaching $1.7 billion by 2025, driven by technological advancements and increasing adoption of minimally invasive procedures. Medtronic and Johnson & Johnson (J&J) are leading players in this market, with J&J's notable product launch being the NEUWAVE microwave ablation system. J&J has also expanded its portfolio through strategic acquisitions, including Auris Health for lung cancer diagnostics and treatment. The market is seeing significant activity in partnerships, collaborations, and product innovations, enhancing treatment quality and expanding applications. These developments position J&J favorably for continued growth and market leadership in tumor ablation. (Sentiment: positive)", "Jumptuit Personal Care, Inc. has launched a new service model dubbed 'The Uber of Personal Care Services,' which aims to bring personal care services directly to customers' homes, addressing the disruption caused by COVID-19. This model leverages mobile technology to provide hyper-personalized beauty services, enhancing cost-efficiency and customer satisfaction. Jumptuit has partnered with leading ridesharing services like Uber and Lyft to facilitate this direct connection between service providers and customers. Additionally, partnerships with major personal care brands such as Johnson & Johnson (JNJ), L'Oréal, and Unilever will enable these companies to gain valuable individualized personal care data and insights, driving more precise supply-demand matching and increased retail home delivery. This innovative approach could potentially boost JNJ's market reach and sales in the personal care segment during and post-pandemic. (Sentiment: positive)"]}
2025-08-08T23:09:03.956878+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:09:03.956908+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:09:03.956934+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:09:03.956989+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:09:03.957117+0800 INFO ENV-new info from env
2025-08-08T23:09:03.957220+0800 INFO ENV-date: 2020-03-24
2025-08-08T23:09:03.957257+0800 INFO ENV-price: {'JNJ': 106.04206085205078}
2025-08-08T23:09:03.957288+0800 INFO ENV-news-JNJ-0: The Global Tumor Ablation Market is projected to grow at a CAGR of 10.9%, reaching $1.7 billion by 2025, driven by technological advancements and increasing adoption of minimally invasive procedures. Medtronic and Johnson & Johnson (J&J) are leading players in this market, with J&J's notable product launch being the NEUWAVE microwave ablation system. J&J has also expanded its portfolio through strategic acquisitions, including Auris Health for lung cancer diagnostics and treatment. The market is seeing significant activity in partnerships, collaborations, and product innovations, enhancing treatment quality and expanding applications. These developments position J&J favorably for continued growth and market leadership in tumor ablation. (Sentiment: positive)
2025-08-08T23:09:03.957359+0800 INFO --------------------------------------------------
2025-08-08T23:09:03.957413+0800 INFO ENV-news-JNJ-1: Jumptuit Personal Care, Inc. has launched a new service model dubbed 'The Uber of Personal Care Services,' which aims to bring personal care services directly to customers' homes, addressing the disruption caused by COVID-19. This model leverages mobile technology to provide hyper-personalized beauty services, enhancing cost-efficiency and customer satisfaction. Jumptuit has partnered with leading ridesharing services like Uber and Lyft to facilitate this direct connection between service providers and customers. Additionally, partnerships with major personal care brands such as Johnson & Johnson (JNJ), L'Oréal, and Unilever will enable these companies to gain valuable individualized personal care data and insights, driving more precise supply-demand matching and increased retail home delivery. This innovative approach could potentially boost JNJ's market reach and sales in the personal care segment during and post-pandemic. (Sentiment: positive)
2025-08-08T23:09:03.957451+0800 INFO --------------------------------------------------
2025-08-08T23:09:03.957482+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:09:03.957510+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:09:03.957537+0800 INFO ==================================================
2025-08-08T23:09:03.957577+0800 INFO AGENT-Step, date: 2020-03-24, run mode: RunMode.TEST, task type: TaskType.SingleAsset
2025-08-08T23:09:03.957604+0800 INFO AGENT-Handling new information
2025-08-08T23:09:04.207629+0800 INFO AGENT-Querying memories
2025-08-08T23:09:04.878319+0800 INFO ##################################################
2025-08-08T23:09:04.878498+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:09:04.878574+0800 INFO AGENT-Short Memory: 25, The Global Tumor Ablation Market is projected to grow at a CAGR of 10.9%, reaching $1.7 billion by 2025, driven by technological advancements and increasing adoption of minimally invasive procedures. Medtronic and Johnson & Johnson (J&J) are leading players in this market, with J&J's notable product launch being the NEUWAVE microwave ablation system. J&J has also expanded its portfolio through strategic acquisitions, including Auris Health for lung cancer diagnostics and treatment. The market is seeing significant activity in partnerships, collaborations, and product innovations, enhancing treatment quality and expanding applications. These developments position J&J favorably for continued growth and market leadership in tumor ablation. (Sentiment: positive)
2025-08-08T23:09:04.878680+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.878743+0800 INFO AGENT-Short Memory: 26, Jumptuit Personal Care, Inc. has launched a new service model dubbed 'The Uber of Personal Care Services,' which aims to bring personal care services directly to customers' homes, addressing the disruption caused by COVID-19. This model leverages mobile technology to provide hyper-personalized beauty services, enhancing cost-efficiency and customer satisfaction. Jumptuit has partnered with leading ridesharing services like Uber and Lyft to facilitate this direct connection between service providers and customers. Additionally, partnerships with major personal care brands such as Johnson & Johnson (JNJ), L'Oréal, and Unilever will enable these companies to gain valuable individualized personal care data and insights, driving more precise supply-demand matching and increased retail home delivery. This innovative approach could potentially boost JNJ's market reach and sales in the personal care segment during and post-pandemic. (Sentiment: positive)
2025-08-08T23:09:04.878812+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.878872+0800 INFO AGENT-Short Memory: 22, The global medical aesthetic market is projected to grow at a CAGR of 11% from 2019 to 2024, driven by the increasing adoption of minimally invasive procedures, technological advancements, and rising demand among men. Key players in the market include Johnson & Johnson (JNJ), which is positioned to benefit from these trends. The market is segmented by product types such as facial aesthetic products, body contouring devices, and cosmetic implants, and by end-users including clinics, medical spas, and beauty centers. North America, Europe, and Asia Pacific are expected to see significant growth, with North America leading due to high consumer awareness and advanced healthcare infrastructure. Strategic initiatives like mergers, acquisitions, and new product developments are critical for maintaining competitive advantage in this rapidly evolving market. (Sentiment: positive)
2025-08-08T23:09:04.878931+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.878985+0800 INFO AGENT-Short Memory: 19, ChroniSense Medical has appointed Bridget Ross as CEO, effective February 10, 2020. Ross brings over three decades of leadership experience, including roles at Henry Schein and Johnson & Johnson (J&J), where she led significant growth and operational efficiencies. Her appointment is expected to drive ChroniSense to a leading position in the disease management space with its Polso wearable device. This move highlights Ross's successful track record at J&J, particularly in commercial operations and product development. Investors in J&J might view this as a positive reflection of the company's ability to cultivate high-caliber leaders who are sought after by other innovative firms. (Sentiment: positive)
2025-08-08T23:09:04.879042+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879096+0800 INFO AGENT-Short Memory: 23, The haircare market in Africa is projected to grow by USD 936.32 million from 2020 to 2024, with a compound annual growth rate (CAGR) of 7%. Key growth drivers include increasing demand for natural haircare products and strategic partnerships between vendors and salons. The market is segmented by product types such as shampoo, conditioner, hair color, hair styling products, and other haircare products, and by distribution channels including offline and online. Geographic segmentation covers Kenya, Nigeria, South Africa, and the rest of Africa. Prominent vendors in this market include major companies like Johnson & Johnson, L'Oréal SA, and Unilever Group, indicating a competitive landscape with significant opportunities for investment. (Sentiment: positive)
2025-08-08T23:09:04.879163+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879215+0800 INFO AGENT-Reflection Memory: 24, The investment decision is based on strong positive short-term sentiment from multiple sources (IDs 16, 17, 18, 20, 22, 23) highlighting JNJ's pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), leadership appointments, and market growth opportunities in medical aesthetics and lateral flow assays. These factors reinforce investor confidence in JNJ's innovation and competitive positioning, despite some unexplained price fluctuations (IDs 6, 11) attributed to broader market or external factors.
2025-08-08T23:09:04.879280+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879330+0800 INFO AGENT-Reflection Memory: 21, The positive price fluctuation (0.0563557191517564) is likely driven by short-term positive sentiment (IDs 16, 17, 18) highlighting JNJ's pharmaceutical advancements, such as the ponesimod NDA submission (ID 17), strong RA drug portfolio (ID 15), and leadership appointments (ID 16). These developments reinforce investor confidence in JNJ's innovation and market positioning, particularly in disease management and healthcare technologies. The reflection-term information (ID 18) explicitly attributes this upward movement to such positive news, suggesting optimism about the company's future prospects despite broader market uncertainties mentioned in other IDs.
2025-08-08T23:09:04.879387+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879436+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:09:04.879493+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879542+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:09:04.879596+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879647+0800 INFO AGENT-Reflection Memory: 18, The positive price fluctuation of 0.0586 is likely influenced by the positive sentiment from short-term news (IDs 17, 16, 12) highlighting JNJ's advancements in pharmaceuticals (e.g., ponesimod NDA submission, RA drug portfolio strength, and surgical robotics growth). These developments may have boosted investor confidence in JNJ's innovation and market positioning, despite the reflection-term information (IDs 6, 14, 11, 1) noting that broader market factors or unmentioned events could also play a role.
2025-08-08T23:09:04.879701+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:04.879755+0800 INFO AGENT-Single asset task
2025-08-08T23:09:31.434781+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:09:31.790019+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:09:31.790119+0800 INFO AGENT-summary reason: The investment decision is based on strong positive short-term sentiment from IDs 22, 23, 25, and 26, highlighting JNJ's leadership in medical aesthetics, growth opportunities in tumor ablation, and partnerships in personal care. Positive price fluctuations (IDs 18, 21, 24) attributed to pharmaceutical advancements and strategic initiatives further reinforce optimism about the stock's future prospects. Despite some unexplained negative price movements (IDs 6, 11), these are linked to broader market factors rather than direct JNJ-related issues. The overall positive sentiment and upward momentum justify a risk-seeking 'buy' decision.
2025-08-08T23:09:31.790504+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 21, 'feedback': -1}]}
2025-08-08T23:09:31.910275+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:09:31.910479+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:09:31.910527+0800 INFO **************************************************
2025-08-08T23:09:31.910564+0800 INFO ENV- current date: 2020-03-25, future date: 2020-03-26
2025-08-08T23:09:31.910632+0800 INFO ENV-Current price: {'JNJ': 106.23782348632812}, future price diff: {'JNJ': -0.060050109143367475}
2025-08-08T23:09:31.910672+0800 INFO ENV-Current news: {'JNJ': ['Dr. Christian Tidona, Founder and Managing Director of BioMed X, has been awarded "Biotechnology CEO Of The Year- Europe" by Business Worldwide Magazine for his innovative approach in biomedical pre-clinical research. BioMed X\'s model combines global crowdsourcing with local incubation, attracting top research talents to tackle complex biomedical challenges. The institute collaborates with major pharmaceutical companies, including Johnson & Johnson (JNJ), to develop new therapies. This partnership highlights JNJ\'s commitment to innovative research and development. The success of BioMed X\'s model and its collaboration with JNJ could positively impact JNJ\'s pipeline and long-term growth in the biotechnology sector. (Sentiment: positive)']}
2025-08-08T23:09:31.910704+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:09:31.910730+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:09:31.910754+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:09:31.910779+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:09:31.910816+0800 INFO ENV-new info from env
2025-08-08T23:09:31.910844+0800 INFO ENV-date: 2020-03-25
2025-08-08T23:09:31.910870+0800 INFO ENV-price: {'JNJ': 106.23782348632812}
2025-08-08T23:09:31.910898+0800 INFO ENV-news-JNJ-0: Dr. Christian Tidona, Founder and Managing Director of BioMed X, has been awarded "Biotechnology CEO Of The Year- Europe" by Business Worldwide Magazine for his innovative approach in biomedical pre-clinical research. BioMed X's model combines global crowdsourcing with local incubation, attracting top research talents to tackle complex biomedical challenges. The institute collaborates with major pharmaceutical companies, including Johnson & Johnson (JNJ), to develop new therapies. This partnership highlights JNJ's commitment to innovative research and development. The success of BioMed X's model and its collaboration with JNJ could positively impact JNJ's pipeline and long-term growth in the biotechnology sector. (Sentiment: positive)
2025-08-08T23:09:31.910925+0800 INFO --------------------------------------------------
2025-08-08T23:09:31.910950+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:09:31.910974+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:09:31.910997+0800 INFO ==================================================
2025-08-08T23:09:31.911027+0800 INFO AGENT-Step, date: 2020-03-25, run mode: RunMode.TEST, task type: TaskType.SingleAsset
2025-08-08T23:09:31.911051+0800 INFO AGENT-Handling new information
2025-08-08T23:09:32.048139+0800 INFO AGENT-Querying memories
2025-08-08T23:09:32.627378+0800 INFO ##################################################
2025-08-08T23:09:32.627453+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:09:32.627491+0800 INFO AGENT-Short Memory: 28, Dr. Christian Tidona, Founder and Managing Director of BioMed X, has been awarded "Biotechnology CEO Of The Year- Europe" by Business Worldwide Magazine for his innovative approach in biomedical pre-clinical research. BioMed X's model combines global crowdsourcing with local incubation, attracting top research talents to tackle complex biomedical challenges. The institute collaborates with major pharmaceutical companies, including Johnson & Johnson (JNJ), to develop new therapies. This partnership highlights JNJ's commitment to innovative research and development. The success of BioMed X's model and its collaboration with JNJ could positively impact JNJ's pipeline and long-term growth in the biotechnology sector. (Sentiment: positive)
2025-08-08T23:09:32.627537+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627568+0800 INFO AGENT-Short Memory: 25, The Global Tumor Ablation Market is projected to grow at a CAGR of 10.9%, reaching $1.7 billion by 2025, driven by technological advancements and increasing adoption of minimally invasive procedures. Medtronic and Johnson & Johnson (J&J) are leading players in this market, with J&J's notable product launch being the NEUWAVE microwave ablation system. J&J has also expanded its portfolio through strategic acquisitions, including Auris Health for lung cancer diagnostics and treatment. The market is seeing significant activity in partnerships, collaborations, and product innovations, enhancing treatment quality and expanding applications. These developments position J&J favorably for continued growth and market leadership in tumor ablation. (Sentiment: positive)
2025-08-08T23:09:32.627599+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627628+0800 INFO AGENT-Short Memory: 26, Jumptuit Personal Care, Inc. has launched a new service model dubbed 'The Uber of Personal Care Services,' which aims to bring personal care services directly to customers' homes, addressing the disruption caused by COVID-19. This model leverages mobile technology to provide hyper-personalized beauty services, enhancing cost-efficiency and customer satisfaction. Jumptuit has partnered with leading ridesharing services like Uber and Lyft to facilitate this direct connection between service providers and customers. Additionally, partnerships with major personal care brands such as Johnson & Johnson (JNJ), L'Oréal, and Unilever will enable these companies to gain valuable individualized personal care data and insights, driving more precise supply-demand matching and increased retail home delivery. This innovative approach could potentially boost JNJ's market reach and sales in the personal care segment during and post-pandemic. (Sentiment: positive)
2025-08-08T23:09:32.627660+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627687+0800 INFO AGENT-Short Memory: 22, The global medical aesthetic market is projected to grow at a CAGR of 11% from 2019 to 2024, driven by the increasing adoption of minimally invasive procedures, technological advancements, and rising demand among men. Key players in the market include Johnson & Johnson (JNJ), which is positioned to benefit from these trends. The market is segmented by product types such as facial aesthetic products, body contouring devices, and cosmetic implants, and by end-users including clinics, medical spas, and beauty centers. North America, Europe, and Asia Pacific are expected to see significant growth, with North America leading due to high consumer awareness and advanced healthcare infrastructure. Strategic initiatives like mergers, acquisitions, and new product developments are critical for maintaining competitive advantage in this rapidly evolving market. (Sentiment: positive)
2025-08-08T23:09:32.627715+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627742+0800 INFO AGENT-Short Memory: 19, ChroniSense Medical has appointed Bridget Ross as CEO, effective February 10, 2020. Ross brings over three decades of leadership experience, including roles at Henry Schein and Johnson & Johnson (J&J), where she led significant growth and operational efficiencies. Her appointment is expected to drive ChroniSense to a leading position in the disease management space with its Polso wearable device. This move highlights Ross's successful track record at J&J, particularly in commercial operations and product development. Investors in J&J might view this as a positive reflection of the company's ability to cultivate high-caliber leaders who are sought after by other innovative firms. (Sentiment: positive)
2025-08-08T23:09:32.627775+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627802+0800 INFO AGENT-Reflection Memory: 24, The investment decision is based on strong positive short-term sentiment from multiple sources (IDs 16, 17, 18, 20, 22, 23) highlighting JNJ's pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), leadership appointments, and market growth opportunities in medical aesthetics and lateral flow assays. These factors reinforce investor confidence in JNJ's innovation and competitive positioning, despite some unexplained price fluctuations (IDs 6, 11) attributed to broader market or external factors.
2025-08-08T23:09:32.627831+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627857+0800 INFO AGENT-Reflection Memory: 27, The investment decision is based on strong positive short-term sentiment from IDs 22, 23, 25, and 26, highlighting JNJ's leadership in medical aesthetics, growth opportunities in tumor ablation, and partnerships in personal care. Positive price fluctuations (IDs 18, 21, 24) attributed to pharmaceutical advancements and strategic initiatives further reinforce optimism about the stock's future prospects. Despite some unexplained negative price movements (IDs 6, 11), these are linked to broader market factors rather than direct JNJ-related issues. The overall positive sentiment and upward momentum justify a risk-seeking 'buy' decision.
2025-08-08T23:09:32.627888+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627914+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:09:32.627942+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.627968+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:09:32.627996+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.628022+0800 INFO AGENT-Reflection Memory: 21, The positive price fluctuation (0.0563557191517564) is likely driven by short-term positive sentiment (IDs 16, 17, 18) highlighting JNJ's pharmaceutical advancements, such as the ponesimod NDA submission (ID 17), strong RA drug portfolio (ID 15), and leadership appointments (ID 16). These developments reinforce investor confidence in JNJ's innovation and market positioning, particularly in disease management and healthcare technologies. The reflection-term information (ID 18) explicitly attributes this upward movement to such positive news, suggesting optimism about the company's future prospects despite broader market uncertainties mentioned in other IDs.
2025-08-08T23:09:32.628050+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:09:32.628078+0800 INFO AGENT-Single asset task
2025-08-08T23:10:06.453687+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:10:06.860570+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:10:06.860696+0800 INFO AGENT-summary reason: The investment decision is based on strong positive short-term sentiment from IDs 22, 24, 25, 26, and 27, highlighting JNJ's leadership in medical aesthetics, growth opportunities in tumor ablation, partnerships in personal care, pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), and leadership appointments. Positive price fluctuations are attributed to these factors, reinforcing optimism about the stock's future prospects. Despite minor negative price movements (IDs 6, 11) linked to broader market factors, the overall sentiment and upward momentum justify a risk-seeking 'buy' decision.
2025-08-08T23:10:06.861249+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 24, 'feedback': -1}]}
2025-08-08T23:10:06.973722+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:10:06.974123+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:10:06.974211+0800 INFO **************************************************
2025-08-08T23:10:06.974256+0800 INFO ENV- current date: 2020-03-26, future date: 2020-03-27
2025-08-08T23:10:06.974395+0800 INFO ENV-Current price: {'JNJ': 112.61741638183594}, future price diff: {'JNJ': 0.026941417885927705}
2025-08-08T23:10:06.974439+0800 INFO ENV-Current news: {'JNJ': ["Researchers at The Hebrew University of Jerusalem and Yissum start-up companies are actively developing innovative technologies to combat COVID-19, including AI-driven drug discovery, biochemical detection tools, and advanced diagnostic capabilities. Proposals have been submitted to the Israel Innovation Authority to fast-track these projects, with a call for industry partnerships to bring these ideas to market. Notable projects include Pepticom's AI technology for identifying peptide drug candidates and Enlivex's medication for severe COVID-19 symptoms. Yissum has a strong track record of converting academic research into commercial solutions, with over 10,750 patents and partnerships with major companies like Johnson & Johnson. Investors in Johnson & Johnson may find potential opportunities in collaborating with Yissum on these emerging COVID-19 technologies. (Sentiment: positive)", 'The global medical micro-electromechanical systems (MEMS) market is projected to grow from US$ 4,710.4 million in 2019 to over US$ 18,319.2 million by 2027, exhibiting a CAGR of 18.5%. Key growth drivers include the rising incidence of chronic diseases like diabetes and cardiac disorders, increasing product launches, and strategic collaborations and acquisitions by major players. Notably, Johnson & Johnson Medical Devices Companies reported a rapid increase in atrial fibrillation prevalence in the Asia Pacific, expected to affect 72 million individuals by 2050. The diagnostic devices segment holds a significant market share due to its high efficiency and real-time patient data analysis. The Asia Pacific region is anticipated to exhibit the highest growth rate in the market. (Sentiment: positive)', 'The global minimally invasive surgical (MIS) instruments market is projected to grow from USD 20.1 billion in 2019 to USD 32.7 billion by 2025, at a CAGR of 8.5%. Key drivers include the advantages of MIS over traditional surgeries and the increasing number of such procedures globally. Johnson & Johnson (JNJ) is a major player in this market, benefiting from its extensive product portfolio and strong market presence. The handheld instruments segment, which commanded the largest market share in 2018, and the cardiothoracic surgery segment, which dominated by type of surgery, are significant growth areas. The Asia Pacific region is expected to register the highest growth, driven by a large patient pool and increasing awareness of modern surgical techniques. (Sentiment: positive)', "Evolve BioSystems, Inc. has announced a collaboration with Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, to study the impact of the probiotic B. infantis EVC001 (marketed as Evivo) on reducing early childhood atopic dermatitis. This condition affects up to 20% of children and is linked to other chronic conditions such as asthma, food allergies, and inflammatory diseases. The study will be a randomized, double-blind, placebo-controlled trial involving infants with a genetic predisposition to allergic conditions. The collaboration aims to demonstrate whether introducing B. infantis EVC001 can prevent the onset of atopic dermatitis and improve long-term health outcomes. This partnership highlights Johnson & Johnson's commitment to innovative healthcare solutions and could potentially open new markets in pediatric health, enhancing their portfolio and long-term growth prospects. (Sentiment: positive)"]}
2025-08-08T23:10:06.974497+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:10:06.974520+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:10:06.974544+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:10:06.974572+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:10:06.974655+0800 INFO ENV-new info from env
2025-08-08T23:10:06.974706+0800 INFO ENV-date: 2020-03-26
2025-08-08T23:10:06.974752+0800 INFO ENV-price: {'JNJ': 112.61741638183594}
2025-08-08T23:10:06.974801+0800 INFO ENV-news-JNJ-0: Researchers at The Hebrew University of Jerusalem and Yissum start-up companies are actively developing innovative technologies to combat COVID-19, including AI-driven drug discovery, biochemical detection tools, and advanced diagnostic capabilities. Proposals have been submitted to the Israel Innovation Authority to fast-track these projects, with a call for industry partnerships to bring these ideas to market. Notable projects include Pepticom's AI technology for identifying peptide drug candidates and Enlivex's medication for severe COVID-19 symptoms. Yissum has a strong track record of converting academic research into commercial solutions, with over 10,750 patents and partnerships with major companies like Johnson & Johnson. Investors in Johnson & Johnson may find potential opportunities in collaborating with Yissum on these emerging COVID-19 technologies. (Sentiment: positive)
2025-08-08T23:10:06.974851+0800 INFO --------------------------------------------------
2025-08-08T23:10:06.974895+0800 INFO ENV-news-JNJ-1: The global medical micro-electromechanical systems (MEMS) market is projected to grow from US$ 4,710.4 million in 2019 to over US$ 18,319.2 million by 2027, exhibiting a CAGR of 18.5%. Key growth drivers include the rising incidence of chronic diseases like diabetes and cardiac disorders, increasing product launches, and strategic collaborations and acquisitions by major players. Notably, Johnson & Johnson Medical Devices Companies reported a rapid increase in atrial fibrillation prevalence in the Asia Pacific, expected to affect 72 million individuals by 2050. The diagnostic devices segment holds a significant market share due to its high efficiency and real-time patient data analysis. The Asia Pacific region is anticipated to exhibit the highest growth rate in the market. (Sentiment: positive)
2025-08-08T23:10:06.974936+0800 INFO --------------------------------------------------
2025-08-08T23:10:06.974974+0800 INFO ENV-news-JNJ-2: The global minimally invasive surgical (MIS) instruments market is projected to grow from USD 20.1 billion in 2019 to USD 32.7 billion by 2025, at a CAGR of 8.5%. Key drivers include the advantages of MIS over traditional surgeries and the increasing number of such procedures globally. Johnson & Johnson (JNJ) is a major player in this market, benefiting from its extensive product portfolio and strong market presence. The handheld instruments segment, which commanded the largest market share in 2018, and the cardiothoracic surgery segment, which dominated by type of surgery, are significant growth areas. The Asia Pacific region is expected to register the highest growth, driven by a large patient pool and increasing awareness of modern surgical techniques. (Sentiment: positive)
2025-08-08T23:10:06.975018+0800 INFO --------------------------------------------------
2025-08-08T23:10:06.975056+0800 INFO ENV-news-JNJ-3: Evolve BioSystems, Inc. has announced a collaboration with Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, to study the impact of the probiotic B. infantis EVC001 (marketed as Evivo) on reducing early childhood atopic dermatitis. This condition affects up to 20% of children and is linked to other chronic conditions such as asthma, food allergies, and inflammatory diseases. The study will be a randomized, double-blind, placebo-controlled trial involving infants with a genetic predisposition to allergic conditions. The collaboration aims to demonstrate whether introducing B. infantis EVC001 can prevent the onset of atopic dermatitis and improve long-term health outcomes. This partnership highlights Johnson & Johnson's commitment to innovative healthcare solutions and could potentially open new markets in pediatric health, enhancing their portfolio and long-term growth prospects. (Sentiment: positive)
2025-08-08T23:10:06.975097+0800 INFO --------------------------------------------------
2025-08-08T23:10:06.975134+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:10:06.975172+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:10:06.975209+0800 INFO ==================================================
2025-08-08T23:10:06.975268+0800 INFO AGENT-Step, date: 2020-03-26, run mode: RunMode.TEST, task type: TaskType.SingleAsset
2025-08-08T23:10:06.975308+0800 INFO AGENT-Handling new information
2025-08-08T23:10:07.292211+0800 INFO AGENT-Querying memories
2025-08-08T23:10:07.884570+0800 INFO ##################################################
2025-08-08T23:10:07.884882+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:10:07.884970+0800 INFO AGENT-Short Memory: 33, Evolve BioSystems, Inc. has announced a collaboration with Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, to study the impact of the probiotic B. infantis EVC001 (marketed as Evivo) on reducing early childhood atopic dermatitis. This condition affects up to 20% of children and is linked to other chronic conditions such as asthma, food allergies, and inflammatory diseases. The study will be a randomized, double-blind, placebo-controlled trial involving infants with a genetic predisposition to allergic conditions. The collaboration aims to demonstrate whether introducing B. infantis EVC001 can prevent the onset of atopic dermatitis and improve long-term health outcomes. This partnership highlights Johnson & Johnson's commitment to innovative healthcare solutions and could potentially open new markets in pediatric health, enhancing their portfolio and long-term growth prospects. (Sentiment: positive)
2025-08-08T23:10:07.885159+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.885325+0800 INFO AGENT-Short Memory: 32, The global minimally invasive surgical (MIS) instruments market is projected to grow from USD 20.1 billion in 2019 to USD 32.7 billion by 2025, at a CAGR of 8.5%. Key drivers include the advantages of MIS over traditional surgeries and the increasing number of such procedures globally. Johnson & Johnson (JNJ) is a major player in this market, benefiting from its extensive product portfolio and strong market presence. The handheld instruments segment, which commanded the largest market share in 2018, and the cardiothoracic surgery segment, which dominated by type of surgery, are significant growth areas. The Asia Pacific region is expected to register the highest growth, driven by a large patient pool and increasing awareness of modern surgical techniques. (Sentiment: positive)
2025-08-08T23:10:07.885423+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.885495+0800 INFO AGENT-Short Memory: 31, The global medical micro-electromechanical systems (MEMS) market is projected to grow from US$ 4,710.4 million in 2019 to over US$ 18,319.2 million by 2027, exhibiting a CAGR of 18.5%. Key growth drivers include the rising incidence of chronic diseases like diabetes and cardiac disorders, increasing product launches, and strategic collaborations and acquisitions by major players. Notably, Johnson & Johnson Medical Devices Companies reported a rapid increase in atrial fibrillation prevalence in the Asia Pacific, expected to affect 72 million individuals by 2050. The diagnostic devices segment holds a significant market share due to its high efficiency and real-time patient data analysis. The Asia Pacific region is anticipated to exhibit the highest growth rate in the market. (Sentiment: positive)
2025-08-08T23:10:07.885578+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.885638+0800 INFO AGENT-Short Memory: 30, Researchers at The Hebrew University of Jerusalem and Yissum start-up companies are actively developing innovative technologies to combat COVID-19, including AI-driven drug discovery, biochemical detection tools, and advanced diagnostic capabilities. Proposals have been submitted to the Israel Innovation Authority to fast-track these projects, with a call for industry partnerships to bring these ideas to market. Notable projects include Pepticom's AI technology for identifying peptide drug candidates and Enlivex's medication for severe COVID-19 symptoms. Yissum has a strong track record of converting academic research into commercial solutions, with over 10,750 patents and partnerships with major companies like Johnson & Johnson. Investors in Johnson & Johnson may find potential opportunities in collaborating with Yissum on these emerging COVID-19 technologies. (Sentiment: positive)
2025-08-08T23:10:07.885702+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.885760+0800 INFO AGENT-Short Memory: 28, Dr. Christian Tidona, Founder and Managing Director of BioMed X, has been awarded "Biotechnology CEO Of The Year- Europe" by Business Worldwide Magazine for his innovative approach in biomedical pre-clinical research. BioMed X's model combines global crowdsourcing with local incubation, attracting top research talents to tackle complex biomedical challenges. The institute collaborates with major pharmaceutical companies, including Johnson & Johnson (JNJ), to develop new therapies. This partnership highlights JNJ's commitment to innovative research and development. The success of BioMed X's model and its collaboration with JNJ could positively impact JNJ's pipeline and long-term growth in the biotechnology sector. (Sentiment: positive)
2025-08-08T23:10:07.885821+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.885881+0800 INFO AGENT-Reflection Memory: 27, The investment decision is based on strong positive short-term sentiment from IDs 22, 23, 25, and 26, highlighting JNJ's leadership in medical aesthetics, growth opportunities in tumor ablation, and partnerships in personal care. Positive price fluctuations (IDs 18, 21, 24) attributed to pharmaceutical advancements and strategic initiatives further reinforce optimism about the stock's future prospects. Despite some unexplained negative price movements (IDs 6, 11), these are linked to broader market factors rather than direct JNJ-related issues. The overall positive sentiment and upward momentum justify a risk-seeking 'buy' decision.
2025-08-08T23:10:07.885943+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.886000+0800 INFO AGENT-Reflection Memory: 24, The investment decision is based on strong positive short-term sentiment from multiple sources (IDs 16, 17, 18, 20, 22, 23) highlighting JNJ's pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), leadership appointments, and market growth opportunities in medical aesthetics and lateral flow assays. These factors reinforce investor confidence in JNJ's innovation and competitive positioning, despite some unexplained price fluctuations (IDs 6, 11) attributed to broader market or external factors.
2025-08-08T23:10:07.886057+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.886119+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:10:07.886176+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.886229+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:10:07.886285+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.886340+0800 INFO AGENT-Reflection Memory: 21, The positive price fluctuation (0.0563557191517564) is likely driven by short-term positive sentiment (IDs 16, 17, 18) highlighting JNJ's pharmaceutical advancements, such as the ponesimod NDA submission (ID 17), strong RA drug portfolio (ID 15), and leadership appointments (ID 16). These developments reinforce investor confidence in JNJ's innovation and market positioning, particularly in disease management and healthcare technologies. The reflection-term information (ID 18) explicitly attributes this upward movement to such positive news, suggesting optimism about the company's future prospects despite broader market uncertainties mentioned in other IDs.
2025-08-08T23:10:07.886398+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:10:07.886457+0800 INFO AGENT-Single asset task
2025-08-08T23:11:38.151121+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:11:38.603708+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:11:38.603822+0800 INFO AGENT-summary reason: The investment decision is based on strong positive short-term sentiment from IDs 33, 32, 31, 30, and 28, which highlight JNJ's collaborations in pediatric health, leadership in the MIS and MEMS markets, and partnerships in innovative biotechnology. Reflection-term information (IDs 27, 24, 21) reinforces positive price fluctuations linked to pharmaceutical advancements and strategic initiatives. Despite unexplained negative price movements (IDs 6, 11), these are attributed to broader market factors, not JNJ-specific issues. Positive momentum and cumulative returns justify a risk-seeking 'buy' decision.
2025-08-08T23:11:38.604229+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 27, 'feedback': 1}]}
2025-08-08T23:11:38.751377+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:11:38.751730+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:11:38.751834+0800 INFO **************************************************
2025-08-08T23:11:38.751910+0800 INFO ENV- current date: 2020-03-27, future date: 2020-03-30
2025-08-08T23:11:38.752255+0800 INFO ENV-Current price: {'JNJ': 109.58334350585938}, future price diff: {'JNJ': -0.07997725872062342}
2025-08-08T23:11:38.752336+0800 INFO ENV-Current news: {'JNJ': ["Johnson // Becker, PLLC has filed a lawsuit against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, alleging that the drug Elmiron causes permanent eye damage and vision loss. The lawsuit claims that Janssen failed to adequately warn patients and physicians about the risks of maculopathy and retinopathy associated with Elmiron. The case, Pelczar v. Teva Branded Pharmaceuticals R&D, et al., was filed in the United States District Court for the District of Connecticut. The plaintiff, diagnosed with permanent retinal injury, asserts that the company did not advise regular eye exams for monitoring vision while using the drug. This legal action could potentially impact Johnson & Johnson's financial standing and investor confidence due to the associated liabilities and reputational risks. (Sentiment: negative)"]}
2025-08-08T23:11:38.752410+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:11:38.752458+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:11:38.752504+0800 INFO ENV-Current momentum: {'JNJ': 1}
2025-08-08T23:11:38.752548+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:11:38.752623+0800 INFO ENV-new info from env
2025-08-08T23:11:38.752673+0800 INFO ENV-date: 2020-03-27
2025-08-08T23:11:38.752718+0800 INFO ENV-price: {'JNJ': 109.58334350585938}
2025-08-08T23:11:38.752766+0800 INFO ENV-news-JNJ-0: Johnson // Becker, PLLC has filed a lawsuit against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, alleging that the drug Elmiron causes permanent eye damage and vision loss. The lawsuit claims that Janssen failed to adequately warn patients and physicians about the risks of maculopathy and retinopathy associated with Elmiron. The case, Pelczar v. Teva Branded Pharmaceuticals R&D, et al., was filed in the United States District Court for the District of Connecticut. The plaintiff, diagnosed with permanent retinal injury, asserts that the company did not advise regular eye exams for monitoring vision while using the drug. This legal action could potentially impact Johnson & Johnson's financial standing and investor confidence due to the associated liabilities and reputational risks. (Sentiment: negative)
2025-08-08T23:11:38.752813+0800 INFO --------------------------------------------------
2025-08-08T23:11:38.752856+0800 INFO ENV-momentum: {'JNJ': 1}
2025-08-08T23:11:38.752897+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:11:38.752938+0800 INFO ==================================================
2025-08-08T23:11:38.753002+0800 INFO AGENT-Step, date: 2020-03-27, run mode: RunMode.TEST, task type: TaskType.SingleAsset
2025-08-08T23:11:38.753045+0800 INFO AGENT-Handling new information
2025-08-08T23:11:38.957880+0800 INFO AGENT-Querying memories
2025-08-08T23:11:39.575292+0800 INFO ##################################################
2025-08-08T23:11:39.575485+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:11:39.575543+0800 INFO AGENT-Short Memory: 35, Johnson // Becker, PLLC has filed a lawsuit against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, alleging that the drug Elmiron causes permanent eye damage and vision loss. The lawsuit claims that Janssen failed to adequately warn patients and physicians about the risks of maculopathy and retinopathy associated with Elmiron. The case, Pelczar v. Teva Branded Pharmaceuticals R&D, et al., was filed in the United States District Court for the District of Connecticut. The plaintiff, diagnosed with permanent retinal injury, asserts that the company did not advise regular eye exams for monitoring vision while using the drug. This legal action could potentially impact Johnson & Johnson's financial standing and investor confidence due to the associated liabilities and reputational risks. (Sentiment: negative)
2025-08-08T23:11:39.575592+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.575648+0800 INFO AGENT-Short Memory: 33, Evolve BioSystems, Inc. has announced a collaboration with Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, to study the impact of the probiotic B. infantis EVC001 (marketed as Evivo) on reducing early childhood atopic dermatitis. This condition affects up to 20% of children and is linked to other chronic conditions such as asthma, food allergies, and inflammatory diseases. The study will be a randomized, double-blind, placebo-controlled trial involving infants with a genetic predisposition to allergic conditions. The collaboration aims to demonstrate whether introducing B. infantis EVC001 can prevent the onset of atopic dermatitis and improve long-term health outcomes. This partnership highlights Johnson & Johnson's commitment to innovative healthcare solutions and could potentially open new markets in pediatric health, enhancing their portfolio and long-term growth prospects. (Sentiment: positive)
2025-08-08T23:11:39.575716+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.575751+0800 INFO AGENT-Short Memory: 32, The global minimally invasive surgical (MIS) instruments market is projected to grow from USD 20.1 billion in 2019 to USD 32.7 billion by 2025, at a CAGR of 8.5%. Key drivers include the advantages of MIS over traditional surgeries and the increasing number of such procedures globally. Johnson & Johnson (JNJ) is a major player in this market, benefiting from its extensive product portfolio and strong market presence. The handheld instruments segment, which commanded the largest market share in 2018, and the cardiothoracic surgery segment, which dominated by type of surgery, are significant growth areas. The Asia Pacific region is expected to register the highest growth, driven by a large patient pool and increasing awareness of modern surgical techniques. (Sentiment: positive)
2025-08-08T23:11:39.575787+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.575821+0800 INFO AGENT-Short Memory: 31, The global medical micro-electromechanical systems (MEMS) market is projected to grow from US$ 4,710.4 million in 2019 to over US$ 18,319.2 million by 2027, exhibiting a CAGR of 18.5%. Key growth drivers include the rising incidence of chronic diseases like diabetes and cardiac disorders, increasing product launches, and strategic collaborations and acquisitions by major players. Notably, Johnson & Johnson Medical Devices Companies reported a rapid increase in atrial fibrillation prevalence in the Asia Pacific, expected to affect 72 million individuals by 2050. The diagnostic devices segment holds a significant market share due to its high efficiency and real-time patient data analysis. The Asia Pacific region is anticipated to exhibit the highest growth rate in the market. (Sentiment: positive)
2025-08-08T23:11:39.575857+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.575891+0800 INFO AGENT-Short Memory: 30, Researchers at The Hebrew University of Jerusalem and Yissum start-up companies are actively developing innovative technologies to combat COVID-19, including AI-driven drug discovery, biochemical detection tools, and advanced diagnostic capabilities. Proposals have been submitted to the Israel Innovation Authority to fast-track these projects, with a call for industry partnerships to bring these ideas to market. Notable projects include Pepticom's AI technology for identifying peptide drug candidates and Enlivex's medication for severe COVID-19 symptoms. Yissum has a strong track record of converting academic research into commercial solutions, with over 10,750 patents and partnerships with major companies like Johnson & Johnson. Investors in Johnson & Johnson may find potential opportunities in collaborating with Yissum on these emerging COVID-19 technologies. (Sentiment: positive)
2025-08-08T23:11:39.575928+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.575962+0800 INFO AGENT-Reflection Memory: 27, The investment decision is based on strong positive short-term sentiment from IDs 22, 23, 25, and 26, highlighting JNJ's leadership in medical aesthetics, growth opportunities in tumor ablation, and partnerships in personal care. Positive price fluctuations (IDs 18, 21, 24) attributed to pharmaceutical advancements and strategic initiatives further reinforce optimism about the stock's future prospects. Despite some unexplained negative price movements (IDs 6, 11), these are linked to broader market factors rather than direct JNJ-related issues. The overall positive sentiment and upward momentum justify a risk-seeking 'buy' decision.
2025-08-08T23:11:39.576001+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.576034+0800 INFO AGENT-Reflection Memory: 34, The investment decision is based on strong positive short-term sentiment from IDs 33, 32, 31, 30, and 28, which highlight JNJ's collaborations in pediatric health, leadership in the MIS and MEMS markets, and partnerships in innovative biotechnology. Reflection-term information (IDs 27, 24, 21) reinforces positive price fluctuations linked to pharmaceutical advancements and strategic initiatives. Despite unexplained negative price movements (IDs 6, 11), these are attributed to broader market factors, not JNJ-specific issues. Positive momentum and cumulative returns justify a risk-seeking 'buy' decision.
2025-08-08T23:11:39.576069+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.576101+0800 INFO AGENT-Reflection Memory: 24, The investment decision is based on strong positive short-term sentiment from multiple sources (IDs 16, 17, 18, 20, 22, 23) highlighting JNJ's pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), leadership appointments, and market growth opportunities in medical aesthetics and lateral flow assays. These factors reinforce investor confidence in JNJ's innovation and competitive positioning, despite some unexplained price fluctuations (IDs 6, 11) attributed to broader market or external factors.
2025-08-08T23:11:39.576136+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.576167+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:11:39.576201+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.576233+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:11:39.576267+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:11:39.576302+0800 INFO AGENT-Single asset task
2025-08-08T23:12:23.577624+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:12:23.988407+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:12:23.988575+0800 INFO AGENT-summary reason: The investment decision is based on strong positive short-term sentiment from IDs 30, 31, 32, and 33, which highlight JNJ's collaborations in pediatric health, leadership in the MIS and MEMS markets, and partnerships in innovative biotechnology. Additionally, the reflection-term information (IDs 27, 34, 24) reinforces positive momentum and cumulative returns, attributing positive price fluctuations to pharmaceutical advancements and strategic initiatives. While ID 35 introduces negative sentiment due to a lawsuit, the reflection-term notes that negative price movements (IDs 6, 11) are linked to broader market factors, not JNJ-specific issues. The overall positive sentiment and upward momentum justify a 'buy' decision as a risk-seeking investor.
2025-08-08T23:12:23.989189+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 29, 'feedback': 1}]}
2025-08-08T23:12:24.134111+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:12:24.134477+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:12:24.134581+0800 INFO **************************************************
2025-08-08T23:12:24.134644+0800 INFO ENV- current date: 2020-03-30, future date: 2020-03-31
2025-08-08T23:12:24.134946+0800 INFO ENV-Current price: {'JNJ': 118.34751892089844}, future price diff: {'JNJ': 0.014134370153363392}
2025-08-08T23:12:24.135045+0800 INFO ENV-Current news: {'JNJ': ["Johnson & Johnson (JNJ) has announced a lead COVID-19 vaccine candidate and a significant partnership with the U.S. Department of Health & Human Services, committing over $1 billion to vaccine research and development. The company plans to initiate Phase 1 human clinical studies by September 2020 and aims for emergency use authorization by early 2021. JNJ is expanding its global manufacturing capacity to produce over one billion vaccine doses, ensuring a rapid and widespread supply. The company is also working on identifying potential antiviral treatments in collaboration with BARDA and other global partners. JNJ's commitment to providing an affordable vaccine on a not-for-profit basis for emergency use underscores its strong position and responsibility in addressing the pandemic. (Sentiment: positive)", "MRI (Management Recruiters International, Inc.) has appointed Joe Mullings as the new Chief Vision Officer to revolutionize the talent access industry using his innovative inbound storytelling strategy. Mullings, with 30 years of experience and a successful track record in executive recruitment, will continue to lead The Mullings Group, which has high-profile clients including Johnson & Johnson (JNJ). His strategy, developed in 2015, leverages video production and social media to attract talent, which could enhance MRI's engagement across various industries. MRI, under new ownership by Bert Miller, generated $190 million in net revenues last year and aims to transform the recruitment industry with a media-forward approach. This strategic move could potentially benefit JNJ by improving their talent acquisition processes through Mullings' proven methods. (Sentiment: positive)", "The Global Anti-Inflammatory Therapeutics Market is projected to grow by USD 27.53 billion from 2020 to 2024, with a CAGR of 6%. Key growth drivers include the increasing prevalence of immune-mediated inflammatory diseases (IMID) and the emergence of novel anti-inflammatory drugs. The market is segmented by applications such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis (MS), and geographically across Asia, Europe, North America, and the rest of the world (ROW). Johnson & Johnson (JNJ) is identified as one of the prominent vendors in this market, alongside other major pharmaceutical companies. This growth potential and JNJ's involvement in the market suggest a positive outlook for the company's investment prospects in the anti-inflammatory therapeutics sector. (Sentiment: positive)", "InvestorsObserver has issued a PriceWatch Alert for Johnson & Johnson (JNJ), providing critical insights for potential investors. The alert offers two types of reports: an options trade idea report and a stock score report. The options report details up to seven different trading strategies, highlighting vital aspects of each option trade idea for JNJ. The stock report evaluates JNJ's investment suitability using a proprietary scoring system that combines short and long-term technical factors with Wall Street's opinion, including a 12-month price forecast. Investors can access these detailed reports to make informed decisions about trading options or investing in JNJ stock. (Sentiment: neutral)", "The Global Arthroscopy Devices Market is projected to grow by USD 1.7 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 6%. Key growth drivers include stringent regulatory policies for medical device approvals and the increasing popularity of physician-owned ambulatory surgical centers (ASCs). Johnson & Johnson is identified as one of the prominent vendors in this market, alongside other major players like Arthrex Inc., Medtronic Plc, and Stryker Corp. The market is segmented by product type, application, end-user, and geography, with significant opportunities in regions such as North America, Europe, and Asia. This growth outlook and Johnson & Johnson's involvement in the market suggest potential positive impacts on their financial performance and market position. (Sentiment: positive)", "The global Insomnia Drugs market is projected to grow by $1.1 billion, driven by a compounded annual growth rate (CAGR) of 5.2%, with Prescription Sleep Aids expected to reach over $3.1 billion by 2025. The United States will maintain a 4% growth momentum, while Germany and other European markets will contribute significantly to regional growth. Japan's market size for Prescription Sleep Aids will reach $178.2 million, and China is expected to grow at 8.2%, adding approximately $334.2 million in market opportunity. Key competitors in this market include Johnson & Johnson, Astellas Pharma, Pfizer, and others. These insights suggest a robust growth trajectory for companies like Johnson & Johnson, making it a potentially attractive investment in the expanding insomnia drugs market. (Sentiment: positive)", "The global In Vitro Diagnostics (IVD) market is projected to grow by $26.7 billion, driven by a 5% compounded annual growth rate (CAGR) through 2025. The Immunoassay/Immunochemistry segment is expected to grow at over 6.1%, reaching over $30.4 billion by 2025. The United States will maintain a 3.8% growth rate, while China is poised for an 8.1% growth, adding approximately $8 billion in market opportunity. Key competitors in this market include Johnson & Johnson, Abbott Laboratories, and Roche Diagnostics, among others. These insights suggest a robust growth trajectory for JNJ's IVD segment, making it a potentially lucrative investment. (Sentiment: positive)"]}
2025-08-08T23:12:24.135245+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:12:24.135296+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:12:24.135339+0800 INFO ENV-Current momentum: {'JNJ': 1}
2025-08-08T23:12:24.135380+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:12:24.135457+0800 INFO ENV-new info from env
2025-08-08T23:12:24.135506+0800 INFO ENV-date: 2020-03-30
2025-08-08T23:12:24.135550+0800 INFO ENV-price: {'JNJ': 118.34751892089844}
2025-08-08T23:12:24.135597+0800 INFO ENV-news-JNJ-0: Johnson & Johnson (JNJ) has announced a lead COVID-19 vaccine candidate and a significant partnership with the U.S. Department of Health & Human Services, committing over $1 billion to vaccine research and development. The company plans to initiate Phase 1 human clinical studies by September 2020 and aims for emergency use authorization by early 2021. JNJ is expanding its global manufacturing capacity to produce over one billion vaccine doses, ensuring a rapid and widespread supply. The company is also working on identifying potential antiviral treatments in collaboration with BARDA and other global partners. JNJ's commitment to providing an affordable vaccine on a not-for-profit basis for emergency use underscores its strong position and responsibility in addressing the pandemic. (Sentiment: positive)
2025-08-08T23:12:24.135649+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.135695+0800 INFO ENV-news-JNJ-1: MRI (Management Recruiters International, Inc.) has appointed Joe Mullings as the new Chief Vision Officer to revolutionize the talent access industry using his innovative inbound storytelling strategy. Mullings, with 30 years of experience and a successful track record in executive recruitment, will continue to lead The Mullings Group, which has high-profile clients including Johnson & Johnson (JNJ). His strategy, developed in 2015, leverages video production and social media to attract talent, which could enhance MRI's engagement across various industries. MRI, under new ownership by Bert Miller, generated $190 million in net revenues last year and aims to transform the recruitment industry with a media-forward approach. This strategic move could potentially benefit JNJ by improving their talent acquisition processes through Mullings' proven methods. (Sentiment: positive)
2025-08-08T23:12:24.135738+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.135779+0800 INFO ENV-news-JNJ-2: The Global Anti-Inflammatory Therapeutics Market is projected to grow by USD 27.53 billion from 2020 to 2024, with a CAGR of 6%. Key growth drivers include the increasing prevalence of immune-mediated inflammatory diseases (IMID) and the emergence of novel anti-inflammatory drugs. The market is segmented by applications such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis (MS), and geographically across Asia, Europe, North America, and the rest of the world (ROW). Johnson & Johnson (JNJ) is identified as one of the prominent vendors in this market, alongside other major pharmaceutical companies. This growth potential and JNJ's involvement in the market suggest a positive outlook for the company's investment prospects in the anti-inflammatory therapeutics sector. (Sentiment: positive)
2025-08-08T23:12:24.135821+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.135862+0800 INFO ENV-news-JNJ-3: InvestorsObserver has issued a PriceWatch Alert for Johnson & Johnson (JNJ), providing critical insights for potential investors. The alert offers two types of reports: an options trade idea report and a stock score report. The options report details up to seven different trading strategies, highlighting vital aspects of each option trade idea for JNJ. The stock report evaluates JNJ's investment suitability using a proprietary scoring system that combines short and long-term technical factors with Wall Street's opinion, including a 12-month price forecast. Investors can access these detailed reports to make informed decisions about trading options or investing in JNJ stock. (Sentiment: neutral)
2025-08-08T23:12:24.135904+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.135943+0800 INFO ENV-news-JNJ-4: The Global Arthroscopy Devices Market is projected to grow by USD 1.7 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 6%. Key growth drivers include stringent regulatory policies for medical device approvals and the increasing popularity of physician-owned ambulatory surgical centers (ASCs). Johnson & Johnson is identified as one of the prominent vendors in this market, alongside other major players like Arthrex Inc., Medtronic Plc, and Stryker Corp. The market is segmented by product type, application, end-user, and geography, with significant opportunities in regions such as North America, Europe, and Asia. This growth outlook and Johnson & Johnson's involvement in the market suggest potential positive impacts on their financial performance and market position. (Sentiment: positive)
2025-08-08T23:12:24.135985+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.136024+0800 INFO ENV-news-JNJ-5: The global Insomnia Drugs market is projected to grow by $1.1 billion, driven by a compounded annual growth rate (CAGR) of 5.2%, with Prescription Sleep Aids expected to reach over $3.1 billion by 2025. The United States will maintain a 4% growth momentum, while Germany and other European markets will contribute significantly to regional growth. Japan's market size for Prescription Sleep Aids will reach $178.2 million, and China is expected to grow at 8.2%, adding approximately $334.2 million in market opportunity. Key competitors in this market include Johnson & Johnson, Astellas Pharma, Pfizer, and others. These insights suggest a robust growth trajectory for companies like Johnson & Johnson, making it a potentially attractive investment in the expanding insomnia drugs market. (Sentiment: positive)
2025-08-08T23:12:24.136066+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.136106+0800 INFO ENV-news-JNJ-6: The global In Vitro Diagnostics (IVD) market is projected to grow by $26.7 billion, driven by a 5% compounded annual growth rate (CAGR) through 2025. The Immunoassay/Immunochemistry segment is expected to grow at over 6.1%, reaching over $30.4 billion by 2025. The United States will maintain a 3.8% growth rate, while China is poised for an 8.1% growth, adding approximately $8 billion in market opportunity. Key competitors in this market include Johnson & Johnson, Abbott Laboratories, and Roche Diagnostics, among others. These insights suggest a robust growth trajectory for JNJ's IVD segment, making it a potentially lucrative investment. (Sentiment: positive)
2025-08-08T23:12:24.136150+0800 INFO --------------------------------------------------
2025-08-08T23:12:24.136192+0800 INFO ENV-momentum: {'JNJ': 1}
2025-08-08T23:12:24.136231+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:12:24.136270+0800 INFO ==================================================
2025-08-08T23:12:24.136334+0800 INFO AGENT-Step, date: 2020-03-30, run mode: RunMode.TEST, task type: TaskType.SingleAsset
2025-08-08T23:12:24.136375+0800 INFO AGENT-Handling new information
2025-08-08T23:12:24.558757+0800 INFO AGENT-Querying memories
2025-08-08T23:12:25.149017+0800 INFO ##################################################
2025-08-08T23:12:25.149131+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:12:25.149169+0800 INFO AGENT-Short Memory: 40, InvestorsObserver has issued a PriceWatch Alert for Johnson & Johnson (JNJ), providing critical insights for potential investors. The alert offers two types of reports: an options trade idea report and a stock score report. The options report details up to seven different trading strategies, highlighting vital aspects of each option trade idea for JNJ. The stock report evaluates JNJ's investment suitability using a proprietary scoring system that combines short and long-term technical factors with Wall Street's opinion, including a 12-month price forecast. Investors can access these detailed reports to make informed decisions about trading options or investing in JNJ stock. (Sentiment: neutral)
2025-08-08T23:12:25.149205+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149232+0800 INFO AGENT-Short Memory: 39, The Global Anti-Inflammatory Therapeutics Market is projected to grow by USD 27.53 billion from 2020 to 2024, with a CAGR of 6%. Key growth drivers include the increasing prevalence of immune-mediated inflammatory diseases (IMID) and the emergence of novel anti-inflammatory drugs. The market is segmented by applications such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis (MS), and geographically across Asia, Europe, North America, and the rest of the world (ROW). Johnson & Johnson (JNJ) is identified as one of the prominent vendors in this market, alongside other major pharmaceutical companies. This growth potential and JNJ's involvement in the market suggest a positive outlook for the company's investment prospects in the anti-inflammatory therapeutics sector. (Sentiment: positive)
2025-08-08T23:12:25.149261+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149286+0800 INFO AGENT-Short Memory: 37, Johnson & Johnson (JNJ) has announced a lead COVID-19 vaccine candidate and a significant partnership with the U.S. Department of Health & Human Services, committing over $1 billion to vaccine research and development. The company plans to initiate Phase 1 human clinical studies by September 2020 and aims for emergency use authorization by early 2021. JNJ is expanding its global manufacturing capacity to produce over one billion vaccine doses, ensuring a rapid and widespread supply. The company is also working on identifying potential antiviral treatments in collaboration with BARDA and other global partners. JNJ's commitment to providing an affordable vaccine on a not-for-profit basis for emergency use underscores its strong position and responsibility in addressing the pandemic. (Sentiment: positive)
2025-08-08T23:12:25.149312+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149340+0800 INFO AGENT-Short Memory: 43, The global In Vitro Diagnostics (IVD) market is projected to grow by $26.7 billion, driven by a 5% compounded annual growth rate (CAGR) through 2025. The Immunoassay/Immunochemistry segment is expected to grow at over 6.1%, reaching over $30.4 billion by 2025. The United States will maintain a 3.8% growth rate, while China is poised for an 8.1% growth, adding approximately $8 billion in market opportunity. Key competitors in this market include Johnson & Johnson, Abbott Laboratories, and Roche Diagnostics, among others. These insights suggest a robust growth trajectory for JNJ's IVD segment, making it a potentially lucrative investment. (Sentiment: positive)
2025-08-08T23:12:25.149368+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149393+0800 INFO AGENT-Short Memory: 41, The Global Arthroscopy Devices Market is projected to grow by USD 1.7 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 6%. Key growth drivers include stringent regulatory policies for medical device approvals and the increasing popularity of physician-owned ambulatory surgical centers (ASCs). Johnson & Johnson is identified as one of the prominent vendors in this market, alongside other major players like Arthrex Inc., Medtronic Plc, and Stryker Corp. The market is segmented by product type, application, end-user, and geography, with significant opportunities in regions such as North America, Europe, and Asia. This growth outlook and Johnson & Johnson's involvement in the market suggest potential positive impacts on their financial performance and market position. (Sentiment: positive)
2025-08-08T23:12:25.149421+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149447+0800 INFO AGENT-Reflection Memory: 27, The investment decision is based on strong positive short-term sentiment from IDs 22, 23, 25, and 26, highlighting JNJ's leadership in medical aesthetics, growth opportunities in tumor ablation, and partnerships in personal care. Positive price fluctuations (IDs 18, 21, 24) attributed to pharmaceutical advancements and strategic initiatives further reinforce optimism about the stock's future prospects. Despite some unexplained negative price movements (IDs 6, 11), these are linked to broader market factors rather than direct JNJ-related issues. The overall positive sentiment and upward momentum justify a risk-seeking 'buy' decision.
2025-08-08T23:12:25.149472+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149497+0800 INFO AGENT-Reflection Memory: 34, The investment decision is based on strong positive short-term sentiment from IDs 33, 32, 31, 30, and 28, which highlight JNJ's collaborations in pediatric health, leadership in the MIS and MEMS markets, and partnerships in innovative biotechnology. Reflection-term information (IDs 27, 24, 21) reinforces positive price fluctuations linked to pharmaceutical advancements and strategic initiatives. Despite unexplained negative price movements (IDs 6, 11), these are attributed to broader market factors, not JNJ-specific issues. Positive momentum and cumulative returns justify a risk-seeking 'buy' decision.
2025-08-08T23:12:25.149524+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149549+0800 INFO AGENT-Reflection Memory: 36, The investment decision is based on strong positive short-term sentiment from IDs 30, 31, 32, and 33, which highlight JNJ's collaborations in pediatric health, leadership in the MIS and MEMS markets, and partnerships in innovative biotechnology. Additionally, the reflection-term information (IDs 27, 34, 24) reinforces positive momentum and cumulative returns, attributing positive price fluctuations to pharmaceutical advancements and strategic initiatives. While ID 35 introduces negative sentiment due to a lawsuit, the reflection-term notes that negative price movements (IDs 6, 11) are linked to broader market factors, not JNJ-specific issues. The overall positive sentiment and upward momentum justify a 'buy' decision as a risk-seeking investor.
2025-08-08T23:12:25.149579+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149605+0800 INFO AGENT-Reflection Memory: 24, The investment decision is based on strong positive short-term sentiment from multiple sources (IDs 16, 17, 18, 20, 22, 23) highlighting JNJ's pharmaceutical advancements (e.g., ponesimod NDA submission, RA drug portfolio strength), leadership appointments, and market growth opportunities in medical aesthetics and lateral flow assays. These factors reinforce investor confidence in JNJ's innovation and competitive positioning, despite some unexplained price fluctuations (IDs 6, 11) attributed to broader market or external factors.
2025-08-08T23:12:25.149631+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149672+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:12:25.149734+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:12:25.149792+0800 INFO AGENT-Single asset task
2025-08-08T23:12:53.994426+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:12:54.499864+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:12:54.500044+0800 INFO AGENT-summary reason: The investment decision is driven by strong positive short-term sentiment from multiple sources (IDs 37, 39, 41, 43) highlighting JNJ's leadership in critical markets (anti-inflammatory therapeutics, IVD, arthroscopy devices), significant partnerships (e.g., U.S. Department of Health & Human Services), and pharmaceutical advancements. Reflection-term information (IDs 24, 27, 34, 36) reinforces positive momentum and cumulative returns, attributing price fluctuations to broader market factors rather than JNJ-specific issues. The positive momentum of the historical stock price further supports a risk-seeking 'buy' decision.
2025-08-08T23:12:54.500688+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 34, 'feedback': 1}]}
2025-08-08T23:12:54.643625+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:12:54.643910+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint/env
2025-08-08T23:12:54.644003+0800 INFO **************************************************
2025-08-08T23:12:54.644055+0800 ERROR ENV-Date series exhausted
2025-08-08T23:12:54.645402+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/test_output/agent/memory_db/brain
2025-08-08T23:12:54.683566+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_output/env
2025-08-08T23:12:54.683730+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/test_output/env
2025-08-08T23:12:54.683836+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/test_output/env
2025-08-08T23:12:54.684187+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/final_result/agent/memory_db/brain
2025-08-08T23:12:54.715093+0800 INFO ✅ 从 portfolio checkpoint 提取了 12 条交易记录
2025-08-08T23:12:54.724537+0800 INFO ✅ 交易结果CSV已保存: results/250808_230347_Qwen_Qwen3-8B_JNJ/trading_results.csv
2025-08-08T23:12:54.724633+0800 INFO ✅ CSV包含 12 条记录，字段: ['timestamp', 'model', 'symbol', 'date', 'action', 'quantity', 'price', 'value', 'portfolio_value', 'current_position', 'cash_remaining', 'status']
2025-08-08T23:12:54.734342+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/charts
2025-08-08T23:12:56.620055+0800 INFO ✅ 所有投资分析图表已生成: results/250808_230347_Qwen_Qwen3-8B_JNJ/charts
2025-08-08T23:12:56.621486+0800 INFO ✅ Trading report generated: results/250808_230347_Qwen_Qwen3-8B_JNJ/report.md
2025-08-08T23:12:56.621890+0800 INFO ✅ Test phase completed
2025-08-08T23:12:56.621928+0800 INFO 📊 Step 3/3: Starting evaluation phase
2025-08-08T23:12:56.622629+0800 INFO 找到结果目录: results/250808_230347_Qwen_Qwen3-8B_JNJ
2025-08-08T23:12:56.624996+0800 INFO SYS-Initializing FinMemAgent
2025-08-08T23:12:56.625102+0800 INFO SYS-Initializing MemoryDB
2025-08-08T23:12:56.725249+0800 INFO SYS-Portfolio type: single-asset
2025-08-08T23:12:56.727980+0800 INFO SYS-Initializing MemoryDB
2025-08-08T23:12:56.820238+0800 INFO ✅ Evaluation phase completed
2025-08-08T23:12:56.820319+0800 INFO 🎉 Complete pipeline finished successfully!
2025-08-08T23:12:56.820542+0800 INFO 📁 Results saved to: results/250808_230347_Qwen_Qwen3-8B_JNJ
2025-08-08T23:12:56.820581+0800 INFO 📊 View report: results/250808_230347_Qwen_Qwen3-8B_JNJ/report.md
2025-08-08T23:12:56.820615+0800 INFO 📈 View charts: results/250808_230347_Qwen_Qwen3-8B_JNJ/charts/
